Vitamin K Deficiency
Overview
Plain-Language Overview
Vitamin K deficiency is a condition where the body lacks enough vitamin K, a nutrient essential for blood clotting. Without sufficient vitamin K, the blood cannot clot properly, leading to easy bruising and excessive bleeding. This deficiency can occur due to poor diet, certain medical conditions, or the use of specific medications. Newborns are particularly at risk because they have low stores of vitamin K at birth. Treatment usually involves vitamin K supplementation to restore normal clotting function.
Clinical Definition
Vitamin K deficiency is a hematologic disorder characterized by a decreased availability of vitamin K, a fat-soluble vitamin necessary for the gamma-carboxylation of glutamic acid residues on clotting factors II, VII, IX, and X, as well as proteins C and S. This post-translational modification is essential for their calcium-binding function and subsequent activation in the coagulation cascade. Deficiency results in impaired synthesis of these functional clotting factors, leading to a bleeding diathesis. Causes include inadequate dietary intake, malabsorption syndromes such as celiac disease or cystic fibrosis, prolonged use of antibiotics that disrupt gut flora, and antagonism by vitamin K antagonists like warfarin. Neonates are particularly susceptible due to sterile intestines and low placental transfer. Clinically, patients present with mucocutaneous bleeding, easy bruising, and prolonged prothrombin time (PT). Laboratory findings typically show isolated prolongation of PT with normal or mildly prolonged activated partial thromboplastin time (aPTT). Treatment involves administration of vitamin K1 (phytonadione) to restore normal clotting factor function.
Inciting Event
- Initiation of broad-spectrum antibiotics that disrupt gut microbiota.
- Poor dietary intake or prolonged fasting leading to decreased vitamin K availability.
- Onset of cholestatic liver disease impairing bile secretion and vitamin K absorption.
- Administration of warfarin or other vitamin K antagonists.
Latency Period
- Bleeding symptoms may develop within 1 to 2 weeks of vitamin K depletion in adults.
- In newborns, hemorrhagic disease can present within the first week of life.
Diagnostic Delay
- Mild bleeding symptoms may be attributed to other causes, delaying recognition of coagulopathy.
- Lack of routine vitamin K level testing and nonspecific presentation can postpone diagnosis.
Clinical Presentation
Signs & Symptoms
- Easy bruising and spontaneous bleeding.
- Mucosal bleeding such as epistaxis and gingival bleeding.
- Hemorrhagic events including gastrointestinal bleeding or hematuria.
- In severe cases, intracranial hemorrhage may occur.
History of Present Illness
- Patients often present with easy bruising, mucosal bleeding, or prolonged bleeding from minor wounds.
- Newborns may show signs of intracranial hemorrhage or bleeding from the umbilical stump.
- History may include recent antibiotic use, poor nutrition, or liver disease symptoms.
Past Medical History
- Chronic liver disease such as cirrhosis or hepatitis.
- History of malabsorption syndromes like cystic fibrosis or celiac disease.
- Previous use of anticoagulants or recent antibiotic therapy.
Family History
- None; vitamin K deficiency is typically acquired rather than inherited.
Physical Exam Findings
- Presence of petechiae or ecchymoses indicating bleeding under the skin.
- Prolonged bleeding from minor cuts or injection sites.
- Possible mucosal bleeding such as gingival bleeding or epistaxis.
Physical Exam Maneuvers
- Assessment of bleeding time to evaluate platelet function and bleeding tendency.
- Performing a tourniquet test to assess capillary fragility and bleeding risk.
Common Comorbidities
- Malabsorption syndromes such as celiac disease or cystic fibrosis.
- Chronic liver disease impairing vitamin K metabolism.
- Use of broad-spectrum antibiotics disrupting gut flora.
- Newborns with immature gut flora and low vitamin K stores.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of vitamin K deficiency is based on clinical suspicion in the presence of bleeding symptoms combined with laboratory evidence of an isolated prolonged prothrombin time (PT) that corrects with vitamin K administration. Activated partial thromboplastin time (aPTT) may be normal or mildly prolonged. Measurement of clotting factor activity shows decreased levels of vitamin K-dependent factors II, VII, IX, and X. Response to vitamin K supplementation, demonstrated by normalization of PT within 24 hours, confirms the diagnosis.
Lab & Imaging Findings
- Prolonged prothrombin time (PT) due to deficiency of vitamin K–dependent clotting factors II, VII, IX, and X.
- Normal or mildly prolonged activated partial thromboplastin time (aPTT) depending on severity.
- Low levels of vitamin K–dependent clotting factors confirmed by factor assays.
- Normal platelet count and normal fibrinogen levels.
- Response to vitamin K administration with normalization of PT confirms diagnosis.
Pathophysiology
Key Mechanisms
- Vitamin K deficiency impairs the gamma-carboxylation of glutamic acid residues on clotting factors II, VII, IX, and X, leading to decreased coagulation activity.
- Reduced activation of vitamin K-dependent proteins results in defective blood clotting and increased bleeding risk.
| Involvement | Details |
|---|---|
| Organs | Liver is the primary organ for synthesis of vitamin K-dependent clotting factors. |
| Small intestine is the main site of dietary vitamin K absorption. | |
| Colon harbors bacteria that synthesize vitamin K2 (menaquinone). | |
| Tissues | Liver tissue synthesizes vitamin K-dependent clotting factors essential for coagulation. |
| Intestinal mucosa facilitates absorption of dietary vitamin K. | |
| Bone tissue requires vitamin K for activation of osteocalcin, important in bone mineralization. | |
| Cells | Hepatocytes are responsible for synthesizing vitamin K-dependent clotting factors. |
| Enterocytes absorb dietary vitamin K in the small intestine. | |
| Gut microbiota synthesize menaquinones (vitamin K2), contributing to vitamin K status. | |
| Chemical Mediators | Vitamin K acts as a cofactor for gamma-glutamyl carboxylase enzyme. |
| Gamma-glutamyl carboxylase catalyzes carboxylation of glutamic acid residues on clotting factors. | |
| Clotting factors II, VII, IX, and X require vitamin K-dependent carboxylation for activation. |
Treatment
Pharmacological Treatments
Vitamin K (phytonadione)
- Mechanism: Serves as a cofactor for gamma-glutamyl carboxylase, enabling activation of clotting factors II, VII, IX, and X
- Side effects: Hypersensitivity reactions, flushing, pain at injection site
Fresh frozen plasma (FFP)
- Mechanism: Provides functional clotting factors to rapidly correct coagulopathy
- Side effects: Volume overload, allergic reactions, transfusion-related acute lung injury
Non-pharmacological Treatments
- Ensure adequate dietary intake of vitamin K-rich foods such as green leafy vegetables.
- Address underlying causes such as malabsorption syndromes to improve vitamin K status.
- Avoid prolonged use of broad-spectrum antibiotics that disrupt gut flora responsible for vitamin K synthesis.
Pharmacological Contraindications
- Vitamin K administration is contraindicated in patients with known hypersensitivity to phytonadione or its components.
- Fresh frozen plasma should be avoided in patients with volume overload or severe heart failure due to risk of exacerbation.
Non-pharmacological Contraindications
- Dietary vitamin K supplementation is inappropriate in patients with severe biliary obstruction without medical intervention.
- Avoidance of antibiotics is contraindicated when treating serious infections despite risk to gut flora.
Prevention
Pharmacological Prevention
- Prophylactic administration of vitamin K1 (phytonadione) in at-risk populations.
- Use of vitamin K supplementation in patients on long-term antibiotics or with malabsorption.
Non-pharmacological Prevention
- Ensuring adequate dietary intake of vitamin K–rich foods such as green leafy vegetables.
- Avoidance of unnecessary prolonged use of broad-spectrum antibiotics.
- Monitoring and managing underlying conditions causing malabsorption.
Outcome & Complications
Complications
- Severe hemorrhage including intracranial bleeding.
- Hemorrhagic shock from uncontrolled bleeding.
- Anemia secondary to chronic blood loss.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Vitamin K Deficiency versus Disseminated Intravascular Coagulation (DIC)
| Vitamin K Deficiency | Disseminated Intravascular Coagulation (DIC) |
|---|---|
| Normal platelet count in vitamin K deficiency | Elevated D-dimer and fibrin degradation products |
| Normal fibrinogen levels in vitamin K deficiency | Thrombocytopenia due to platelet consumption |
| Isolated prolonged PT with possible mild aPTT prolongation | Prolonged PT and aPTT with low fibrinogen levels |
Vitamin K Deficiency versus Hemophilia A
| Vitamin K Deficiency | Hemophilia A |
|---|---|
| Prolonged PT with possible mild aPTT prolongation | Isolated prolonged aPTT with normal PT |
| Deficiency of vitamin K-dependent factors II, VII, IX, X | Factor VIII deficiency confirmed by assay |
| Normal bleeding time unless severe deficiency | Normal bleeding time |
Vitamin K Deficiency versus Liver Disease
| Vitamin K Deficiency | Liver Disease |
|---|---|
| Normal liver enzymes in vitamin K deficiency | Elevated liver enzymes (AST, ALT) |
| Normal factor V levels since it is not vitamin K dependent | Decreased synthesis of all clotting factors including factor V |
| Isolated prolonged PT with or without mild aPTT prolongation | Prolonged PT and aPTT with low albumin |